Log in

NASDAQ:EIDXEidos Therapeutics Stock Price, Forecast & News

$49.53
+0.22 (+0.45 %)
(As of 06/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$48.07
Now: $49.53
$50.98
50-Day Range
$40.00
MA: $45.76
$53.15
52-Week Range
$24.50
Now: $49.53
$66.56
Volume112,472 shs
Average Volume98,217 shs
Market Capitalization$1.91 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.26
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California.
Read More
Eidos Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.14 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EIDX
CUSIPN/A
CIKN/A
Phone415-887-1471

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.69 million
Book Value$4.57 per share

Profitability

Net Income$-37,830,000.00

Miscellaneous

Employees28
Market Cap$1.91 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableNot Optionable

Receive EIDX News and Ratings via Email

Sign-up to receive the latest news and ratings for EIDX and its competitors with MarketBeat's FREE daily newsletter.

Eidos Therapeutics (NASDAQ:EIDX) Frequently Asked Questions

How has Eidos Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Eidos Therapeutics' stock was trading at $43.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EIDX shares have increased by 12.9% and is now trading at $49.53. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Eidos Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eidos Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eidos Therapeutics.

When is Eidos Therapeutics' next earnings date?

Eidos Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Eidos Therapeutics.

How were Eidos Therapeutics' earnings last quarter?

Eidos Therapeutics Inc (NASDAQ:EIDX) issued its quarterly earnings data on Friday, May, 8th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.07. View Eidos Therapeutics' earnings history.

What price target have analysts set for EIDX?

10 brokers have issued 1 year target prices for Eidos Therapeutics' shares. Their forecasts range from $34.00 to $80.00. On average, they anticipate Eidos Therapeutics' share price to reach $57.80 in the next twelve months. This suggests a possible upside of 16.7% from the stock's current price. View analysts' price targets for Eidos Therapeutics.

Has Eidos Therapeutics been receiving favorable news coverage?

News stories about EIDX stock have been trending negative this week, according to InfoTrie. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Eidos Therapeutics earned a news sentiment score of -2.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutEidos Therapeutics.

Who are some of Eidos Therapeutics' key competitors?

What other stocks do shareholders of Eidos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eidos Therapeutics investors own include Crispr Therapeutics (CRSP), Exelixis (EXEL), Micron Technology (MU), Aduro BioTech (ADRO), Agile Therapeutics (AGRX), ImmunoGen (IMGN), Pfizer (PFE), Roku (ROKU), Sangamo Therapeutics (SGMO) and Clovis Oncology (CLVS).

Who are Eidos Therapeutics' key executives?

Eidos Therapeutics' management team includes the following people:
  • Dr. Neil Kumar, CEO & Director (Age 40)
  • Dr. Isabella Graef M.D., Founder & Board Advisor (Age 54)
  • Dr. Uma Sinha, Chief Scientific Officer (Age 62)
  • Dr. Cameron Turtle, Chief Bus. Officer (Age 29)
  • Dr. Hoyoung Huh, Consultant (Age 50)

When did Eidos Therapeutics IPO?

(EIDX) raised $101 million in an IPO on Wednesday, June 20th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Barclays was co-manager.

What is Eidos Therapeutics' stock symbol?

Eidos Therapeutics trades on the NASDAQ under the ticker symbol "EIDX."

Who are Eidos Therapeutics' major shareholders?

Eidos Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.68%), Cormorant Asset Management LP (2.85%), Redmile Group LLC (1.79%), Perceptive Advisors LLC (1.78%), Lord Abbett & CO. LLC (0.75%) and Driehaus Capital Management LLC (0.60%). Company insiders that own Eidos Therapeutics stock include Bridgebio Pharma Llc, Bridgebio Pharma, Inc, Cameron Turtle, Christine Siu, Eric Aguiar, Jonathan C Fox, Neil Kumar, Rajeev M Shah and Uma Sinha. View institutional ownership trends for Eidos Therapeutics.

Which institutional investors are selling Eidos Therapeutics stock?

EIDX stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Morgan Stanley, Redmile Group LLC, Perceptive Advisors LLC, Citigroup Inc., SG Americas Securities LLC, UBS Group AG, and Alps Advisors Inc.. Company insiders that have sold Eidos Therapeutics company stock in the last year include Cameron Turtle, Christine Siu, Jonathan C Fox, and Uma Sinha. View insider buying and selling activity for Eidos Therapeutics.

Which institutional investors are buying Eidos Therapeutics stock?

EIDX stock was purchased by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Eventide Asset Management LLC, Invesco Ltd., BlackRock Inc., Aviva PLC, Geode Capital Management LLC, AXA, and Driehaus Capital Management LLC. Company insiders that have bought Eidos Therapeutics stock in the last two years include Bridgebio Pharma Llc, Bridgebio Pharma, Inc, Eric Aguiar, Neil Kumar, and Rajeev M Shah. View insider buying and selling activity for Eidos Therapeutics.

How do I buy shares of Eidos Therapeutics?

Shares of EIDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eidos Therapeutics' stock price today?

One share of EIDX stock can currently be purchased for approximately $49.53.

How big of a company is Eidos Therapeutics?

Eidos Therapeutics has a market capitalization of $1.91 billion and generates $26.69 million in revenue each year. The company earns $-37,830,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Eidos Therapeutics employs 28 workers across the globe.

What is Eidos Therapeutics' official website?

The official website for Eidos Therapeutics is www.eidostx.com.

How can I contact Eidos Therapeutics?

Eidos Therapeutics' mailing address is 101 MONTGOMERY STREET SUITE 2000, SAN FRANCISCO CA, 94104. The company can be reached via phone at 415-887-1471 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.